Immunic Inc.

There are plenty of multiple sclerosis treatments on the market but Immunic is hopeful that its late-stage candidate vidofludimus calcium is going to be a gamechanger given its effectiveness across th

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

Since biotech valuations on public markets peaked in September 2021, the sector has had to contend with reduced financing availability and harsher conditions for deal-making. In December 2023, Scrip

“As economic, social, and environmental crises magnify, the world is undergoing some of the most turbulent times we’ve ever seen,” observed Emmanuelle Quilès , worldwide vice president, cardiovascula